Intensity Therapeutics, Inc.
INTS
NASDAQ·Healthcare·Biotechnology·Mkt cap $9.6M
$3.57
▲ +0.56%
P/E
—
Mkt Cap
$9.6M
52-Wk Range
$3.21–$43.50
52-Week Range
$3.21 - $43.50
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 49.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary INT230-6 drug candidate with multi-indication potential
- Strategic partnerships with major pharmaceutical companies (Merck, Bristol-Myers Squibb)
- Combination therapy approach reducing development risk
- Clinical-stage pipeline positioned in high-value oncology market
Bear Case
1 risk
- Very high volatility (beta 3.1). Expect 3x market swings. Position size accordingly.
Growth
Stable outlook
Phase 2 clinical trial progression and positive efficacy data
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Falling
-25.7% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying INTS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 11, 2026
Reported EPS of -$1.11 vs -$0.87 consensus (-27.2% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-27.2%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Citi · Aug 11, 2026
vs Industry
How INTS stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related